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The development of plant biotechnologies has been very rapid in recent times, especially in the 
developed countries. The technologies have created a new branch of biotechnology known as 
molecular farming, where plants are engineered to produce pharmaceutical and technical proteins in 
large quantities. An evaluation of the status of plant biotechnology development in Africa revealed that 
majority of the countries that are involved in biotech activities are still at the level of tissue culture 
applications. This calls for urgent and sincere commitments on the part of the various stakeholders in 
Africa, especially the governments, to the development of biotechnology capacity.  
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INTRODUCTION 
 
Since the first report of plant genetic transformation in the 
80s, the technology has been deployed to produce the 
first-generation genetically modified (GM) plants, the 
herbicide-tolerant (Ht) and insect-resistant (Bacillus 
thuringiensis [Bt]) crops, that were engineered basically 
to increase farmers productivity. The first-generation GM 
crops have proven to be of tremendous benefits to the 
countries that have adopted them. For example, as high 
as 70 to 85% reduction in the application of herbicides 
and pesticides were reported for India and China (Bennett 
et al., 2006; Huang et al., 2003), hence impacting 
positively on the cost of these chemicals and overall 
production costs. The introduction of the Bt crops has led 
to reduction in insect damage and has reduced the labor 
costs by about half in South Africa (Morse et al., 2005) 
and  by 66% in Australia (Fitt, 2003). It was estimated 
that Bt-cotton in the US led to 860,000 kg reduction in 
pesticide use and increased farmers’ net income by $100 
million (Gianessi et al., 2002, cited in Konde, 2006). 
Additionally, these first generation GM crops have 
increased the yield at unprecedented level, for example, 
a striking 87% yield increase was recorded in the field 
trial of Bt cotton in India (Qaim, 2003) and additional 1.6 
million Metric tons maize production was achieved with 
Bt-maize in the US (Gianessi et al., 2002, cited in Konde, 
2006). 
Plant biotechnology (plant biotech) has since moved on 
to engineering second-generation GM crops, which in-
corporate traits that lead to enhanced nutritional contents 
of the farm products, for example, the engineering of the 
-carotene biosynthetic pathway in rice for enhanced 
provitamin A content (Ye et al., 2000) and the engineering 
of tomatoes for increased folate production (Diaz de la 
Garza et al., 2007). The technology is actually on a flight 
at the moment, with the third-generation GM crops that 
are engineered as bio-factories for the production of 
different kinds of recombinant proteins for pharmaceutical 
and industrial applications. This plant-based production of 
biopharmaceuticals and technical proteins is known as 
molecular farming (Schillberg et al., 2005). Interestingly, 
there appears to be somewhat more favorable public 
perception about the plant molecular farming (PMF) 
crops than the first- and second generation GM crops 
(Costa-Font and Mossialos, 2005), possibly because of 
the need and potential benefits of the products and also 
probably because most of these crops are not intended 
for consumption but are only being used as production 
platforms. With the huge technological advances within 
short period, plant biotech is indeed poised to be the 
leading plant science of the century, but the question is, 
is Africa part of these developments? This review 
discusses the evolution and the development of PMF and 
overviews the various plant-derived recombinant pharma-
ceutical and non-pharmaceutical proteins that are at 
different stages of developments. It also highlights the 
status of development of PMF technologies in the 
developing countries, with emphasis on Africa and then 
discuss capacity building in African biotech development.  
Obembe        4301 
 
 
 
Table 1. Comparison of different production systems for recombinant proteins [data adapted from Biemelt and Sonnewald, (2005)]. 
 
System Costs of 
Production 
Time 
effort 
Scale-up 
capacity 
Product 
quality 
Glycosylation Contamination 
risk 
Storage Social 
acceptance level 
Bacteria Low  Low High Low None Endotoxins Medium/ -20°C High 
Yeast Medium Medium High Medium Incorrect Low Medium/ -20°C High 
Mammalian cell culture High High Very Low Very high Correct Viruses, oncogens Difficult/ Liquid N2 Medium 
Transgenic animals High High Low Very High Correct Viruses, oncogens Difficult Low 
Plant cell cultures Medium Medium Medium High Minor differences Low Medium/ -20°C High 
Transgenic plants Low High Very high High Minor differences Low Easy/Room temperature Medium 
 
 
 
THE EVOLUTION AND DEVELOPMENT OF 
PLANT MOLECULAR FARMING 
 
Plants have been used right from the dawn of 
ages, as sources of natural medicaments for 
treating various ailments. In addition to being the 
major resource for drug exploration, plants are still 
being used hugely in complementary and 
alternative medicine in many developing countries 
and nowadays, in the developed countries 
(Fønnebø et al., 2007). Up till early 1970s, bioactive 
compounds of drugs were being extracted, 
purified and synthesized solely from plants. How-
ever, synthetic drugs, whose evolution started with 
the production of aspirin by the drug company 
Bayer in 1899, took the centre stage in 
pharmaceutical production, for the greater parts of 
the 20th century. Since the advent of genetic 
engineering technologies in the 1970s, living 
systems, such as bacteria, yeast and animal cells 
have been used as production systems for many 
valuable therapeutic and diagnostic proteins 
(Andersen and Krummen 2002; Harvey et al., 
2002), thereby complementing chemical synthesis 
and extraction of bioactive compounds from living 
materials. However, due to the production con-
straints of these systems, which include poor 
quality and low yield, the development of plant-
based expression systems for recombinant 
proteins has been well-accepted as a promising 
cost-effective alternative platform for the production 
of safer and cheaper biopharmaceutical proteins. 
The comparative advantages of the plant-based 
system over the existing expression systems, 
which are summarized in Table 1, are the incentive 
for this. 
Since the first recombinant plant-made pharma-
ceutical protein, in which the human growth 
hormone was expressed in tobacco and sunflower 
(Barta et al., 1986), there have been significant 
advances in the development of PMF technologies, 
which have largely demonstrated that plants could 
be turned into bio-factories for the large-scale 
production of recombinant proteins (Table 2). 
Moreover, plants are now being engineered to 
mimic mammalian pattern of protein processing, 
that make these recombinant proteins fold properly 
and maintain their structural and functional 
integrity. As such, they are being made to produce 
even more complex functional mammalian 
proteins with therapeutic activity, such as human 
serum proteins and growth regulators, antibodies, 
vaccines, hormones, cytokines, enzymes and 
antibodies. With increasing demand for bio-
pharmaceuticals, coupled with the high costs and 
inefficiency of the established production systems, 
there is now pressure to increase production 
capacity. Hence attention is being shifted to 
transgenic plants as the new generation bio-
reactors. 
 
 
OVERVIEW OF PLANT-DERIVED 
RECOMBINANT PROTEINS  
 
Several candidate recombinant proteins with 
potential use as vaccines have been expressed in 
plants, since the first plant-derived vaccine-
relevant protein was reported 20 years ago (He et 
al., 2008; Hull et al., 2005; Liu et al., 2005; 
Maclean et al., 2007; Marquet-Blouin et al., 2003; 
McCormick et al., 2008; Mett et al., 2007; 
Moravec et al., 2007; Nochi et al., 2007; Qian et 
al., 2008; Rosales-Mendoza et al., 2009; Santi et 
al., 2006; Satyavathi et al., 2003; Sharma et al., 
2008;   Streatfield  and   Howard   2003;   Tacket 
et al., 2000; Tiwari et al., 2009; Tregoning et al., 
2005). Several plant-produced vaccine candidates 
are at different stages of clinical trials (Table 3). 
However, only one veterinary vaccine, the NDV 
vaccine for poultry, has been approved by the US 
Department of Agriculture (USDA) (www.the 
poultrysite.com). 
Also, several biologically active full antibodies 
have been produced in plants (Huang et al., 2001; 
Nicholson et al., 2005; Ramessar et al., 2008; 
Villani et al., 2008). Of all the different plant-derived 
monoclonal antibodies  presently  being  tested  in  
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Table 2. Major advances in the development of PMF [data adapted from Schillberg  and Twyman (2007)]. 
 
Year Major Advance Reference 
1986 Human growth hormone produced in tobacco and sunflower – the first plant-derived recombinant therapeutic protein Barta et al., 1986 
1989 Full-size IgG produced in tobacco – the first demonstration of the ability of plants to assemble heterologous complex 
biomolecules 
Hiatt et al., 1989 
1990 Human serum albumin produced in tobacco and potato – the first native human protein produced in plants Sijmons et al., 1990 
1992 Hepatitis B virus surface antigen produced in tobacco – the first plant-derived vaccine candidate Mason et al., 1992 
1992 -amylase produced in tobacco – the  first plant-derived industrial enzyme Pen et al., 1992 
1995 First secretory IgA produced in tobacco Ma et al., 1995 
1995 E. coli heat-labile enterotoxin (LT-B) expression in tobacco and potato – the  first proof-of-concept of a plant edible vaccine Haq et al., 1995 
1996 Artificial elastin expression in tobacco– the first plant-derived protein polymer Zhang et al., 1996 
1997 First clinical trial using recombinant bacterial antigen delivered in a transgenic potato  Tacket et al., 1998 
1997 Avidin produced in maize – the first commercialized plant-derived protein Hood et al., 1997 
1999 First glycan analysis of plant-produced recombinant glycoprotein Cabanes-Macheteau et al., 
1999 
2000 Human growth hormone produced in tobacco chloroplasts Staub et al., 2000 
2000 Triple helix assembly and processing of human collagen produced in tobacco Ruggiero et al., 2000 
2001 First multi-component vaccine candidate expressed in potato –cholera toxin B and A2 subunits, rotavirus enterotoxin and 
enterotoxigenic Escherichia coli fimbrial antigen fusions for protection against several enteric diseases 
Yu and Langridge, 2001 
2001 Glycan modification of a foreign protein produced in a plant host using a human glycosyltransferase Bakker et al., 2001 
2003 Expression and assembly of a functional antibody in algae Mayfield et al., 2003 
2003 Bovine trypsin – the first marketed plant-derived protein, targeted towards a broad market Woodard et al., 2003 
2004 Glyco-engineered moss strains – the first plant system to be commercialized as bioreactor Decker and Reski, 2004 
(http://www.greenovation.com) 
2005 First demonstration of most ‘humanized’ protein glycosylation patterns in plant production system Huether et al., 2005 
2006 Antibody against Hepatitis B – the first commercialized plant-derived antibody (marketed in Cuba) Pujol et al., 2005 
2006 HN proteins of Newcastle disease virus – world’s first regulatory approval (USDA) for a plant-made vaccine for animals (poultry) Vermin and Waltz, 2006 
2008 CaroRX – the first antibody vaccine for human application (prevention of tooth decay), to be approved by the EU Kaiser, 2008 
2009 Highest transient expression of full-sized IgG antibody in plants Vézina et al., 2009 
2009 Highest recombinant protein accumulation in plants so far – 70% total soluble protein for a proteinaceous antibiotic [40] Oey et al., 2009 
 
 
 
the clinical trials (Table 3), only one antibody for 
production of Hepatitis B Virus vaccine has been 
commercialized (Pujol et al., 2005). Several human 
proteins have been expressed in the plants (Arlen 
et al., 2007; Bai et al., 2007; Edelbaum et al., 1992; 
Elias-Lopez et al., 2008; Gutiérrez-Ortega et al., 
2005; Musa et al., 2009; Nykiforuk et al., 2006; 
Sadhu and Reddy, 2003; Weise et al., 2007), 
many of which are at various stages of clinical 
trials or commercialization. It is noteworthy that 
Merispase®, a gastric lipase from the Meristem 
Therapeutics is already on the market (Sharma 
and Sharma, 2009, Table 3).  
Plant-produced antimicrobial  nutraceutics, such  
as human lactoferrin and lysozymes are now 
commercially available (Table 3). The Cobento 
Biotechnology’s Arabidopsis-derived human intrinsic 
factor, which is to be used against vitamin B12 
deficiency has just been approved by the EU (Key 
et al., 2008) and now commercially available 
(Sharma and Sharma, 2009).  
   
 
 
 
 
Table 3. Plant-derived pharmaceuticals in clinical stages of development or on market.  
 
Product Disease Plant Clinical trial status Company 
Vaccines 
Hepatitis B antigen (HBsAg) Hepatitis B  Lettuce 
Potato  
Phase I  
Phase II 
Thomas Jefferson University, USA,  
Arizona State University 
Fusion proteins, including epitopes from 
rabies 
Rabies Spinach Phase I completed Thomas Jefferson University, USA 
Cancer vaccine  Non-Hodgkin’s lymphoma Tobacco Phase II Large Scale Biology, USA 
Vibrio Cholerae Cholera Potato Phase I Arizona State University 
Heat-labile toxin B subunit of E. coli  Diarrhea Maize  
Potato 
Phase I 
Phase I 
ProdiGenea, USA 
Arizona State University 
Capsid protein Norwalk virus Diarrhea Potato  
Tomato 
Phase I Arizona State University 
Antigen Feline parvovirus (Dogs) Tobacco Advanced Large Scale Biology 
Antigen Papilloma virus (Rabbit) Tobacco Early  Large Scale Biology 
HN protein of Newcastle disease virus Newcastle disease (Poultry) Tobacco 
suspension cells 
USDA Approved Dow Agro Sciences 
Viral vaccine mixture Diseases of horses, dogs, and 
birds 
Tobacco 
suspension cells 
Phase I Dow Agro Sciences 
Poultry vaccine Coccidiosis infection Canola Phase II  Guardian Biosciences 
Gastroenteritis virus (TGEV) capsid protein Piglet gastroenteritis Maize Phase I ProdiGenea  
Antibodies 
CaroRX Dental caries Tobacco EU approved as medical advice Planet Biotechnology, USA 
DoxoRX Side-effects of cancer therapy Tobacco Phase I completed Planet Biotechnology 
RhinoRX Common cold Tobacco Phase I completed Planet Biotechnology 
Fv antibodies Non-Hodgkin’s lymphoma Tobacco Phase I Large Scale Biology 
IgG (ICAM1) Common cold Tobacco Phase I Planet Biotechnology 
Antibody against Hepatitis B Vaccine purification  Tobacco On market CIGB, Cuba 
Therapeutic human proteins 
Gastric lipase, Merispase® Cystic fibrosis Maize  On market Meristem Therapeutics  
-Galactosidase Fabry disease Tobacco Phase I Planet Biotechnology 
Lactoferon™ (-interferon) Hepatitis B & C Duckweed Phase II Biolex, USA 
Interleukin Crohn’s disease Tobacco  Field trails Southern Crop Protection and Food 
Research Centre, Canada 
Fibrinolytic drug (thrombolytic drug) Blood clot Duckweed Phase I Biolex 
Human glucocerebrosidase  Gaucher disease Carrot suspension 
cells 
Marketing expected in 2010 Protalix Biotherapeutics, Israel 
Insulin  Diabetes Safflower Commercialization expected for 
2010 
SemBioSys, Canada 
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Table 3. Contd 
 
Apolipoprotein Cardiovascular Safflower Phase I SemBioSys 
Nutraceuticals 
Human intrinsic Factor, Coban Vitamin B12 deficiency Arabidopsis On market  Cobento Biotech AS 
Human lactoferrin Anti-infection, anti-inflammatory Rice Advanced, on market as fine chemical Ventria, USA 
Human lysozyme Anti-infection, anti-inflammatory Rice Advanced, on market as fine chemical  Ventria 
Immunosphere™ Food additive for shrimps Safflower Marketing expected in 2010  SemBioSys 
 
Data adapted from Basaran and Rodríguez-Cerezo (2008), Kaiser (2008), Key et al. (2008), Lau and Sun (2009), Sharma and Sharma (2009) and Spök et al. (2008). 
aWinded up activity.
 
 
 
The plant-derived industrial proteins, most of 
which are enzymes, including avidin, trypsin, -
glucuronidase, peroxidase, laccase, cellulose, 
amongst others are now commercialized (Basaran 
and Rodríguez-Cerezo, 2008). The molecular 
farming of cell-wall deconstructing enzymes holds 
great promise for the biofuel industry, with respect 
to the production of cellulosic ethanol (Lee et al., 
2008; Sticklen, 2008). Non-hydrolytic proteins with 
cell wall disrupting and loosening properties, such 
as the carbohydrate binding modules of cell wall 
deconstructing enzymes and the expansins  have 
been demonstrated to alter cell wall structure 
(Obembe et al., 2007a; Obembe et al., 2007b),  
as such are good candidate PMF proteins for the 
production of cellulosic ethanol. 
 
 
STATUS OF PLANT MOLECULAR FARMING 
DEVELOPMENT IN THE DEVELOPING 
COUNTRIES 
 
It is exactly a decade after one of the foremost 
campaigners for plant biotech in Africa, Florence 
Wambugu gave a wakeup call to all stakeholders 
in Africa to rally and stimulate research and deve-
lopment in plant biotech for solving, especially, the 
food insecurity problem of the continent (Wambugu, 
1999). An assessment of the status of plant 
biotech development for generating the first and 
the second generation GM crops shows that 
Africa does not seem ready to catch up with the 
trends in other parts of the world, as most of the 
counties are still at the stage of tissue culture 
applications, while genetic engineering is limited 
to only three countries, South Africa, Kenya and 
Zimbabwe (Ayele et al., 2006; Cohen, 2005), with 
South Africa as the leader (Thomson, 2008). The 
groups of Edward Rybicki and Jennifer Thomson 
both of the University of Cape Town are the trail 
blazers for the entire continent. Recently, they 
reported the world’s first maize streak virus (MSV) 
resistant transgenic maize (Shepherd et al., 
2007). This GM maize is also the first all-African 
produced transgenic crop plant, as well as the first 
genetically engineered crop developed wholly by 
a developing country (Sinha, 2007). 
With respect to the development of PMF 
technologies in the developing countries, an 
analysis of recent data compiled by Basaran and 
Rodríguez-Cerezo (2008) indeed revealed that 
the developing countries account for 37% of the 
world PMF activities while the developed countries 
account for 63%. Although, this seems encouraging, 
however, on further analysis, the margin between 
the two worlds widens remarkably with respect to 
the actual numbers of PMF centers. The analysis 
shows that 87% of the PMF centers are located in 
the developed countries, while the developing 
countries can only boast of 13%, which is just 
one-third of the numbers of centers located in  the  
US (Figure 1). 
It should be noted that Africa, through the sole 
activities of Rybicki’s group, accounts for less than 
1% of the world PMF centers. The research 
activities of his laboratory in the development of 
plant-derived vaccines have secured a seat for 
Africa on the plant biotech flight! In his review article, 
published in the January 2009 issue of Drug 
Discovery Today and titled “Plant-produced 
vaccines: promise and reality”, Rybicki illustrated the 
evolution of the PMF activities in his laboratory, 
which dates back to 1997 (Rybicki, 2009). It was 
such a delight to read the success story of PMF 
technologies in his laboratory, from the early years 
of little beginnings to the landmark advances in 
recent times, in the development of plant-produced 
tumor vaccine, papillomavirus vaccines (Maclean 
et al., 2007; Varsani et al., 2006), which could be 
made available at affordable prices, thereby 
placing them at the reach of the resource-poor 
patients. This feat is particularly inspiring, as we 
can only hope that these pioneering activities 
would eventually rob off on the rest of the 
continent, with time, especially when biotech 
capacity improves generally.   
 
 
BUILDING CAPACITY FOR PLANT 
BIOTECHNOLOGIES IN AFRICA 
 
Discussion on the problem of wide spread 
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inadequacy in infrastructural capacity for biotech 
generally, in Africa cannot be over flogged and the 
solution to the prevailing dearth of plant biotech research 
and development activities, in particular, in most of the 
continent, is believed not to be beyond reach. Several 
models and recommendations have been proposed for 
taking the continent out of the woods, with respect to 
plant biotech development, in particular (Ayele et al., 
2006; Delmer, 2005; Konde, 2006; Machuka, 2001; Ozor, 
2008; Singh and Daar, 2008; Wambugu, 1999). It 
remains to be seen whether the various stakeholders in 
Africa really have the strong will, like other developing 
countries in Asia and Latin America, to drive this through 
and not to be disinterested further by recent external 
negative attitudes against GM crops, which is keeping the 
technology out of Africa (Paarlberg, 2008). The impacts 
of biotech on the economic growth of these emerging 
economies are glaring for all. As such, I believe that 
biotech can also work in Africa if it is working elsewhere. 
The strategies adopted by some of these other 
developing economies are worth publicizing, to serve as 
good templates for Africa’s biotech development. In this 
regard, a paper on the biotech exploits and bio-economic 
growth of India was presented at the Knowledge 
Management Africa (KMA) Conference 2009, which was 
held in Dakar, Senegal from 4th through to 7th May, 2009 
(Obembe and Dike, 2009). Some of the recommenda-
tions   presented   at  the  Conference,  based  on  India’s 
strategic plans, are highlighted below. 
 
1) Deliberate and aggressive awareness campaigns 
about the new technology, with respect to the potential 
benefits and to allay public fear over their safety. 
2) Revisiting the educational policies to encourage and 
stimulate interest of young people in Science and 
Technology at the primary and secondary levels. Also, 
the redesigning of the curricula at the tertiary level to 
make biotech courses compulsory component. This 
agrees with other viewpoints that the development of man 
power for biotech base should be long term trainings and 
not through workshop and seminars. 
3) Provision of basic infrastructures for low-techniques, 
such as tissue culture and nucleotide analyses for the 
Universities, as well as funding of research activities of 
researchers in these Universities. 
4) Provision of motivation and incentives in order to retain 
the highly educated human resources and to make those 
trained overseas return home.  
5) Investment in basic infrastructures-reliable power 
supply, portable  water,  roads,  modern  information  and 
telecommunications facilities. ICT Infrastructures in parti-
cular, will enhance acquisition of knowledge and its app- 
lication and also reduce transaction costs. 
6) Setting up specialized biotech centers. This is in line 
with the NEPAD initiatives of establishing four specialized 
biotech centers of excellence across Africa. This initiative 
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will ensure capacity building in core and priority areas 
where expertise and resources already exist. 
7) Establishment of collaborative ventures/Technology 
Park/incubators with private companies, to facilitate that 
biotech products get to the market. This sort of venture 
will eventually be self-funded and also ensure placements 
for trained workforce. Alternatively, the Government can 
provide loans to small and medium scale companies that 
might be interested in such ventures. 
8) Attraction of foreign investments and fostering inter-
national partnership and linkages, all of which can only 
be established when there are functional basic facilities 
on ground. 
9) Setting up/strengthening of existing biosafety, regulatory 
and Intellectual property bodies to formulate more efficient 
biotech policies and guidelines and also to set up testing 
and certification facilities. 
 
 
CONCLUDING REMARKS 
 
By and large, for any meaningful change to happen at the 
national levels for instance there must be substantial 
financial commitment on the parts of the various 
governments. The African countries cannot expect to get 
the same results as other developing countries when 
most of them are committing less than 0.01% of their 
Gross Domestic Products (GDPs) to Science and 
Technology on the whole, while countries like India, 
Korea, Brazil and Cuba are committing more than 1.0% 
of their GDPs to biotech research and development 
alone. The transformations that are being celebrated in 
the bio-economies of these countries today attest to the 
saying that “your harvest is a proportion of your sowing”. 
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